Two of the most frequently compared non-steroidal SARMs in the research literature are LGD-4033 (Ligandrol) and RAD-150 (TLB-150). Both are full androgen receptor agonists studied for their anabolic activity in skeletal muscle and bone tissue models, yet they differ meaningfully in their chemical structure, published research depth, and pharmacokinetic profiles.
This guide provides a direct, research-focused comparison of LGD-4033 and RAD-150 to help researchers understand which compound is more appropriate for a given study design. For broader context on how SARMs work as a compound class, see our Complete Guide to SARMs.
Quick Comparison: LGD-4033 vs RAD-150
| Property | LGD-4033 (Ligandrol) | RAD-150 (TLB-150) |
|---|---|---|
| Chemical class | Arylpropionamide SARM | Benzoate ester of RAD-140 |
| AR binding | High affinity, full agonist | High affinity, full agonist |
| Human clinical data | Yes — Phase I & II published | Limited — preclinical primary |
| Half-life (human) | ~24–36 hours | Longer than RAD-140 (ester-extended) |
| Aromatization | No | No |
| HPG suppression | Documented, dose-dependent | Expected; less published data |
| Primary research use | Muscle wasting, bone density | Pharmacokinetic profiling vs RAD-140 |
LGD-4033 (Ligandrol): Overview
LGD-4033 is among the most extensively studied non-steroidal SARMs. Originally developed by Ligand Pharmaceuticals and advanced by Viking Therapeutics as VK5211, it has a substantial published literature spanning preclinical rodent models and early-phase human trials. The landmark Basaria et al. (2013) Phase I study in The Journals of Gerontology documented dose-proportional pharmacokinetics, lean body mass increases, and HPG axis suppression in healthy male volunteers at doses of 0.1–1.0 mg/day over 21 days.
LGD-4033 binds the androgen receptor with high affinity and acts as a full agonist in skeletal muscle and bone tissue while showing reduced androgenic activity in prostate tissue compared to testosterone — the key selectivity characteristic studied in its development program. It does not aromatize to estrogen and does not convert to DHT via 5-alpha reductase.
Its ~24–36 hour elimination half-life in humans supports once-daily dosing protocols. Phase II data from Viking Therapeutics in hip fracture recovery patients showed statistically significant increases in lean body mass, advancing the compound’s clinical evidence base further than most other SARMs in its class.
Best suited for research into: Muscle wasting models, sarcopenia, bone density, HPG axis suppression kinetics, comparative SARM pharmacology.
→ View LGD-4033 (Ligandrol) research compound
RAD-150 (TLB-150): Overview
RAD-150, designated TLB-150 in some research contexts, is a benzoate ester prodrug of RAD-140 (Testolone). Its development rationale centers on ester modification to alter the pharmacokinetic profile of the parent compound — specifically to extend the release and potentially smooth out the plasma concentration curve compared to RAD-140’s relatively rapid absorption and metabolism.
RAD-140 itself has a published preclinical literature showing high anabolic-to-androgenic ratios in rodent models, neuroprotective activity in certain cell-line studies, and a pharmacokinetic profile characterized by rapid oral absorption. RAD-150’s ester modification is intended to modulate these characteristics — making it a compound of particular interest for pharmacokinetic comparison studies.
The published literature on RAD-150 specifically (as distinct from RAD-140) is considerably more limited than that of LGD-4033. Most available data relates to RAD-140, with RAD-150 primarily characterized through its structural relationship to the parent compound. Human pharmacokinetic data comparable to the Basaria et al. LGD-4033 study does not currently exist for RAD-150 in the published literature.
Best suited for research into: Ester-modified SARM pharmacokinetics, extended-release androgen receptor agonist profiles, comparison studies vs RAD-140.
→ View RAD-150 (TLB-150) research compound
Mechanism of Action: How They Compare
Both LGD-4033 and RAD-150 (via RAD-140 as the active form after ester hydrolysis) act as full agonists at the androgen receptor in skeletal muscle tissue. The molecular distinction lies in their chemical scaffolds:
LGD-4033 is an arylpropionamide-class SARM — a non-steroidal scaffold that binds directly to the ligand-binding domain of the AR and induces a specific receptor conformation favoring anabolic over androgenic gene transcription.
RAD-140 (the active component of RAD-150 after ester cleavage) belongs to a different structural class — a pyrazolo[1,5-a][1,3,5]triazine scaffold. Its interaction with the AR differs structurally from LGD-4033’s, with published preclinical data suggesting a potentially higher anabolic-to-androgenic ratio in rodent models.
The practical implication for researchers: both compounds activate the AR in muscle tissue as full agonists, but they do so via structurally distinct mechanisms. Studies examining tissue-specific AR coactivator recruitment or receptor conformation may yield different findings with each compound.
Pharmacokinetics: Key Differences
LGD-4033 has a well-characterized human PK profile: ~24–36 hour half-life, high oral bioavailability, dose-proportional plasma concentrations. This is documented in published peer-reviewed data.
RAD-150 introduces ester pharmacokinetics. After oral administration, the benzoate ester undergoes hydrolysis (primarily in plasma and liver) to release RAD-140 as the active compound. The ester modification is designed to slow this process, extending the effective half-life compared to RAD-140 administered directly. However, published human PK data for RAD-150 specifically is currently absent from the peer-reviewed literature.
For researchers where precise pharmacokinetic characterization is important to study design, LGD-4033’s published human PK data gives it a significant advantage over RAD-150 in terms of experimental predictability.
HPG Axis Suppression
Both compounds suppress the hypothalamic-pituitary-gonadal (HPG) axis via androgen receptor agonism — this is a mechanistic consequence of any AR agonist and should be expected in experimental models. LGD-4033’s suppressive effects are quantitatively documented in the Basaria et al. study, including magnitude at various doses and time to recovery after cessation (~5 weeks). Comparable quantitative HPG suppression data for RAD-150 is not published in the peer-reviewed literature.
For researchers designing protocols involving hormonal endpoints, LGD-4033 offers substantially better published reference data for predicting and interpreting HPG effects.
Which Compound for Which Research Question?
Choose LGD-4033 if: Your research requires a well-characterized SARM with published human pharmacokinetic and safety data. Ideal for studies into muscle wasting, bone density, HPG axis suppression kinetics, or any design where peer-reviewed dose-response data is needed as a reference.
Choose RAD-150 if: Your research interest is specifically in ester-modified SARM pharmacokinetics — for example, comparing prodrug vs parent compound release profiles, or studying whether ester modification alters tissue distribution or receptor engagement timing relative to RAD-140.
For most standard anabolic SARM research protocols, LGD-4033’s superior evidence base makes it the more defensible reference compound. RAD-150 is the better choice when the pharmacokinetic differences introduced by the ester moiety are themselves the research question.
Sourcing Both Compounds
Chemyo Sarms supplies both LGD-4033 and RAD-150 as research-grade compounds with independent third-party COA documentation confirming identity, purity, and concentration for each batch.
Frequently Asked Questions
Is RAD-150 stronger than LGD-4033?
“Stronger” is not a meaningful pharmacological comparison without specifying the endpoint, model, and dose. In preclinical rodent models, RAD-140 (the active compound from RAD-150) has shown higher anabolic-to-androgenic ratios than some other SARMs, but direct comparative preclinical studies between LGD-4033 and RAD-150 specifically are limited in the published literature. Neither compound is approved for human use, and no validated “strength” comparison for human outcomes exists.
Does RAD-150 have more side effects than LGD-4033?
There is insufficient published human data to compare the side effect profiles of RAD-150 and LGD-4033 directly. LGD-4033 has a published Phase I safety dataset (Basaria et al., 2013) reporting no serious adverse events at doses up to 1.0 mg/day for 21 days. No equivalent published human safety data exists for RAD-150.
What is the difference between RAD-140 and RAD-150?
RAD-140 is the parent compound — an androgen receptor agonist in the pyrazolo-triazine structural class. RAD-150 (TLB-150) is a benzoate ester of RAD-140, designed to modify its pharmacokinetic profile. After administration, RAD-150 is hydrolyzed to release RAD-140 as the active form.
Can LGD-4033 and RAD-150 be studied together?
Combination protocols are at the discretion of the researcher and their study design requirements. Both compounds target the same receptor (AR) via full agonism, so combination studies would need to account for potential additive HPG suppression and receptor saturation effects.
Both compounds are sold by Chemyo Sarms strictly as research compounds for laboratory use. Not intended for human consumption. For educational reference only.